Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

British Journal of Cancer

Volumn 98, Issue 1, 2008, Pages 86-90

  Han, K S ^a   Joung, J Y ^a   Kim, T S ^a   Jeong, I G ^a   Seo, H K ^a   Chung, J ^a   Lee, K H ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Metastasis; Transitional cell carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; INFECTION; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; VISCERAL METASTASIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; VINBLASTINE;

EID: 38049081245     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604113     Document Type: Article

References (27)

1. Bamias A, Tiliakos I, Karali MD, Dimopoulos MA (2006) Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol 17: 553-561
2. Bellmunt J, Cos J, Clèries R, Pérez M, Ribas A, Eres N, Murio JE, Margarit C, Baselga J (2002) Feasibility trial of methotrexate- paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 20: 673-685
3. Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Sole LA, Baselga J (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80: 1966-1972
4. Culine S (2002) The present and future of combination chemotherapy in bladder cancer. Semin Oncol 29: 32-39
5. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B, James N (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94: 1395-1401
6. de Wit R, European Organization for Research and Treatment (2003) Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97: 2120-2126
7. Dreicer R, Gustin DM, See WA, Williams RD (1996) Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 156: 1606-1608
8. Garcia JA, Dreicer R (2006) Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 24: 5545-5551
9. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W (2000) Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921-1927
10. Krege S, Rembrink V, Börgermann C, Otto T, Rübben H (2001) Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol 165: 67-71
11. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15: 1853-1857
12. Meluch AA, Greco FA, Burris III HA, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 19: 3018-3024
13. Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 2876-2881
14. Pectasides D, Pectasides E, Economopoulos T (2007) Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 33: 177-190
15. Petrioli R, Frediani B, Manganelli A, Barbanti G, De Capua B, De Lauretis A, Salvestrini F, Mondillo S, Francini G (1996) Comparison between a cisplatin-containing regimen and a carboplatin containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77: 344-351
16. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270
17. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg LR (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461-469
18. Sternberg CN, Calabrò F, Pizzocaro G, Marini L, Schnetzer S, Sella A (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92: 2993-2998
19. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS (2006) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24: 3451-3457
20. Sweeney CJ, Williams SD, Finch DE, Bihrle R, Foster RS, Collins M, Fox S, Roth BJ (1999) A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 86: 514-518
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
22. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ (1995) Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154: 1719-1722
23. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB (2002) Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20: 937-940
24. von der Maase H, Andersen L, Crinò L, Weinknecht S, Dogliotti L (1999) Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10: 1461-1465
25. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077
26. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608
27. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, Loehrer PJ (1997) Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15: 589-593